Researchers have identified regions of DNA that appear to influence both Parkinson’s disease risk and sex-specific factors, including age of menstruation and menopause. Variants in these regions had different effects on gene activity in men and women, which scientists believe could underlie the higher prevalence of the neurodegenerative disease…
People with Parkinson’s disease who have more severe nonmotor symptoms are less likely to feel empowered to manage their own disease, and also are less likely to get regular physical exercise, a new study shows. These findings “suggest that to promote physical activity and patient activation there is a…
Eye scans may help identify who’s at risk of developing Parkinson’s several years before symptoms first become apparent and doctors can make a diagnosis of the disease, a study suggests. Researchers observed that two specific structures in the retina, a light-sensitive layer of tissue at the back of…
WTX-A, a small molecule in the pipeline of Wavebreak, was able to reduce the formation of toxic clumps of the alpha-synuclein protein, a hallmark of Parkinson’s disease, in cells and mouse models of the disease. While it’s still too early to tell if WTX-A can stop the…
People with a specific variation in a gene that helps control the immune system are less likely to develop Parkinson’s disease and other neurological disorders, a new study reports. Scientists think that people carrying this genetic variant might benefit from vaccines that could help to delay the progression of…
Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease. The company will continue under the Serina name and expects to submit an investigational new drug application (IND) for SER-252 to the U.S. Food…
NE3107, BioVie’s experimental oral therapy for Parkinson’s disease, is showing promise as a first-line therapy to ease motor symptoms and as a possible strategy to enhance the benefits of standard carbidopa and levodopa therapy. According to data from a Phase 2 clinical trial and a preclinical study with…
A high dose of the investigational oral therapy mesdopetam led to a significant and clinically meaningful reduction in levodopa-induced dyskinesia — the uncontrolled, involuntary movements and muscle stiffness common in Parkinson’s disease patients undergoing treatment — in a Phase 2 study, according to an in-depth examination of trial…
A mutation in the GBA1 gene is associated with an increased risk of Parkinson’s disease among people of African ancestry, a new study shows. While other mutations in GBA1 have previously been linked with Parkinson’s, this mutation, which is particularly common in people of African ancestry, has not been associated before with…
Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with Parkinson’s disease, indicate the treatment may slow the progression of motor symptoms. The LixiPark (NCT03439943) trial is evaluating lixisenatide’s effectiveness as add-on therapy in 156 people with early…
Get regular updates to your inbox.